alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2018460EN.01001101.xml

| 21.12.2018 | EN | Official Journal of the European Union | C 460/11 |
| --- | --- | --- | --- |

21.12.2018

EN

Official Journal of the European Union

C 460/11

---

COUNCIL DECISION

of 17 December 2018

appointing one member of the Management Board of the European Chemicals Agency

(2018/C 460/09)

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (1), and in particular Article 79 thereof,

Whereas:

| (1) | Article 79 of Regulation (EC) No 1907/2006 provides that the Council is to appoint one representative from each Member State as members of the Management Board of the European Chemicals Agency (‘the Management Board’). |
| --- | --- |

(1)

Article 79 of Regulation (EC) No 1907/2006 provides that the Council is to appoint one representative from each Member State as members of the Management Board of the European Chemicals Agency (‘the Management Board’).

| (2) | By its Decision of 25 September 2014 (2) the Council appointed one member of the Management Board. |
| --- | --- |

(2)

By its Decision of 25 September 2014 (2) the Council appointed one member of the Management Board.

| (3) | The Government of Croatia has informed the Council of its intention to nominate the current Croatian representative on the Management Board and has submitted a nomination for a second term of office running until 26 September 2022, |
| --- | --- |

(3)

The Government of Croatia has informed the Council of its intention to nominate the current Croatian representative on the Management Board and has submitted a nomination for a second term of office running until 26 September 2022,

HAS ADOPTED THIS DECISION:

Article 1

Mr Bojan VIDOVIĆ, of Croatian nationality, born on 22 May 1976, is hereby appointed member of the Management Board of the European Chemicals Agency for the period from 26 September 2018 to 26 September 2022.

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 17 December 2018.

For the Council

The President

E. KÖSTINGER

---

(1)  OJ L 396, 30.12.2006, p. 1.

1

(2)  OJ C 350, 25.9.2014, p. 3.

2

---
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
The schedule contains summary financial information extracted from Winthrop
Residential Associates III, A Limited Partnership and is qualified in its
entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                                    9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                       2,783,000
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                       4,974,000
<DEPRECIATION>                              (3,018,000)
<TOTAL-ASSETS>                               4,890,000
<CURRENT-LIABILITIES>                                0
<BONDS>                                      2,490,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   2,084,000
<TOTAL-LIABILITY-AND-EQUITY>                 4,890,000
<SALES>                                              0
<TOTAL-REVENUES>                             2,154,000
<CGS>                                                0
<TOTAL-COSTS>                                  703,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             151,000
<INCOME-PRETAX>                              1,289,000
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          1,289,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,289,000
<EPS-BASIC>                                      47.67
<EPS-DILUTED>                                    47.67



</TABLE>
Douglas A. PANNELL, Jr., petitioner, v. UNITED STATES.

No. 12-9919.

Supreme Court of the United States

May 28, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
James R. CLAYWORTH, et al., petitioners v. PFIZER, INC., et al.

No. 12-1241.

Supreme Court of the United States

June 3, 2013.

Petition for writ of certiorari to the Court of Appeal of California, First Appellate District, denied.

Justice ALITO took no part in the consideration or decision of this petition.
##### 



Exhibit 31.1
 CERTIFICATE PURSUANT TO
RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
  1.
    
    I have reviewed this annual report on Form 10-K of Liberty Acquisition Holdings Corp.;2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;4.
    
    I am responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and I have:
 (a)
    
    Designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being
prepared;(b)
    
    Evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such
evaluation; and(c)
    
    Disclosed in this report any change in the registrants internal control over financial
reporting that occurred during the registrants most recent fiscal quarter (the
registrants fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrants internal control
over financial reporting; and
 5.
    
    I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrants auditors and the audit committee of registrants board of
directors (or persons performing the equivalent functions):
 (a)
    
    All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrants ability to record, process, summarize and report financial information;
and(b)
    
    Any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrants internal control over financial reporting.
 March 11, 2008
    /s/ Nicolas BerggruenNicolas BerggruenPresident and Chief Executive Officer
(principal executive officer,  principal financial officer
and principal accounting officer)
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1344 Introduced in House (IH)]

109th CONGRESS
  1st Session
                                H. R. 1344

 To amend the Wild and Scenic Rivers Act to designate a segment of the 
Farmington River and Salmon Brook in the State of Connecticut for study 
 for potential addition to the National Wild and Scenic Rivers System, 
                        and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 16, 2005

 Mrs. Johnson of Connecticut (for herself, Mr. Larson of Connecticut, 
Mr. Simmons, Ms. DeLauro, and Mr. Shays) introduced the following bill; 
            which was referred to the Committee on Resources

_______________________________________________________________________

                                 A BILL

 
 To amend the Wild and Scenic Rivers Act to designate a segment of the 
Farmington River and Salmon Brook in the State of Connecticut for study 
 for potential addition to the National Wild and Scenic Rivers System, 
                        and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Lower Farmington River and Salmon 
Brook Wild and Scenic River Study Act''.

SEC. 2. DESIGNATION OF ADDITIONAL SEGMENT OF FARMINGTON RIVER AND 
              SALMON BROOK IN CONNECTICUT FOR STUDY FOR POTENTIAL 
              ADDITION TO NATIONAL WILD AND SCENIC RIVERS SYSTEM.

    (a) Findings.--The Congress finds the following:
            (1) The Farmington River and Salmon Brook in the State of 
        Connecticut possess important resource values, including 
        wildlife, ecological, and scenic values, and historic sites and 
        a cultural past important to America's heritage.
            (2) There is a longstanding interest among State and local 
        officials, area residents, and river and brook users in 
        undertaking a concerted cooperative effort to manage the river 
        and brook in a productive and meaningful way.
    (b) Designation.--Section 5(a) of the Wild and Scenic Rivers Act 
(16 U.S.C. 1276(a)) is amended by adding at the end the following new 
paragraph:
    ``(139) Lower Farmington River and Salmon Brook, Connecticut.--The 
segment of the Farmington River downstream from the segment designated 
as a recreational river by section 3(a)(156) to its confluence with the 
Connecticut River, and the segment of the Salmon Brook including its 
mainstem and east and west branches.''.
    (c) Time for Submission.--Not later than three years after the date 
of the enactment of this Act, the Secretary of the Interior shall 
submit to Congress a report containing the results of the study 
required by the amendment made by subsection (b).
    (d) Authorization of Appropriations.--There are authorized to be 
appropriated such sums as may be necessary to carry out this Act.
                                 <all>
```
EX PARTE Earnest Lee WALKER, Sr.

CR-17-0221

Court of Criminal Appeals of Alabama.

January 29, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Mand. pet. dismissed.
Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Universal American Corp. (the "Registrant") for the quarter
ended September 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Richard A. Barasch, Chief Executive Officer of the Registrant, and Robert A.
Waegelein, Chief Financial Officer of the Registrant, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that to the best of his knowledge:



Date: November 4, 2010

/s/ RICHARD A. BARASCHRichard A. Barasch Chief Executive OfficerDate: November 4, 2010

/s/ ROBERT A. WAEGELEINRobert A. Waegelein Chief Financial Officer


A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed filed with the Securities and
Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section. This certification is not to be
incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934, irrespective of any general incorporation language contained in
such filing.

---



QuickLinks
Generic Drugs Can Help Promote Health Equity

Health equity is achieved when all people can attain their full 

health potential. One significant way to promote health equity 

is access to high-quality, affordable medications required to 

manage a person’s health needs. 

Increasing access and addressing the high cost of medicines 

is a top priority of the Administration, the Department of Health 

and Human Services, and FDA. FDA’s Office of Generic Drugs

supports robust generic drug development, which can increase 

access to medications. This can improve health outcomes, 

lower health care costs for individuals and society, and reduce 

health disparities.

Generic Drugs Can Improve Medication Adherence

By measuring medication adherence and its impact on health outcomes across different groups, health care 

providers and policymakers can identify and address the barriers and facilitators that affect medication-taking 

behavior and health equity. Studies demonstrate that medication nonadherence leads to worse clinical outcomes, 

lower quality of life, and higher health care costs, and costs the U.S. health care system an estimated $300 billion 

per year. 

A recent study showed that patients who were initiated on generic drugs were more likely to adhere to their 

medications compared with those initiated on brand drugs. Health policies that reduce out-of-pocket cost of 

medication could lead to better medication adherence, better health outcomes, and overall health equity.

Generic Drugs Can Help Improve Access to Medication 

The vision of FDA’s Office of Minority Health and Health Equity is a world where 

health equity is a reality for all. FDA’s Office of Generic Drugs supports this vision 

by increasing access to medications, which can improve health and reduce health 

disparities among racial and ethnic minority populations and those with 

ower incomes. 

Generic drugs can help make needed medications more affordable for the U.S. 

public. Competition helps make drugs more widely available and generally less 

expensive, allowing millions of patients to access needed medicines more easily. 

The availability of generic drugs can help reduce the cost of health care for individuals and families and lead to 

increased access to medications. 

Generic drugs can help stabilize the supply of medicines and reduce the risk of drug shortages. Efforts to 

improve access to generic drugs for racial and ethnic minority and other diverse populations aim to reduce 

health disparities and promote health care equity. Removing barriers to generic drug development and market 

entry helps consumers get access to the medicines they need at more affordable prices.

Learn more about generic drugs. Visit www.FDA.gov/GenericDrugs.

fda.gov
Ramond L. WALKER, Jr., DOC #R44816, Appellant, v. STATE of Florida, Appellee.

Case No. 2D18-3621

District Court of Appeal of Florida, Second District.

Opinion filed June 5, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 03-7472

STEPHEN ROY GRATTON,

 Petitioner - Appellant,

 versus

CHARLIE J. CEPAK, Warden, Broad River

Correctional Institution; SOUTH CAROLINA

DEPARTMENT OF CORRECTIONS; STATE OF SOUTH

CAROLINA; CHARLES MOLONY CONDON, Attorney

General, State of South Carolina,

 Respondents - Appellees.

Appeal from the United States District Court for the District of

South Carolina, at Greenville. Terry L. Wooten, District Judge.

(CA-01-1937-6-25AK)

Submitted: January 30, 2004 Decided: March 9, 2004

Before LUTTIG, GREGORY, and DUNCAN, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Stephen Roy Gratton, Appellant Pro Se. Tracey Colton Green, OFFICE

OF THE ATTORNEY GENERAL OF SOUTH CAROLINA, Columbia, South

Carolina, for Appellees.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
- 2 -

PER CURIAM:

Stephen Roy Gratton seeks to appeal the district court’s

orders denying relief on his petition filed under 28 U.S.C. § 2254

(2000) and denying his motion to reconsider. An appeal may not be

taken from the final order in a habeas corpus proceeding unless a

circuit justice or judge issues a certificate of appealability. 28

U.S.C. § 2253(c)(1) (2000). A certificate of appealability will

not issue absent “a substantial showing of the denial of a

constitutional right.” 28 U.S.C. § 2253(c)(2) (2000). A prisoner

satisfies this standard by demonstrating that reasonable jurists

would find that his constitutional claims are debatable and that

any dispositive procedural rulings by the district court are also

debatable or wrong. See Miller-El v. Cockrell, 537 U.S. 322, 336

(2003); Slack v. McDaniel, 529 U.S. 473, 484 (2000); Rose v. Lee,

252 F.3d 676, 683 (4th Cir 2001). We have independently reviewed

the record and conclude that Gratton has not made the requisite

showing. Accordingly, we deny a certificate of appealability and

dismiss the appeal. We dispense with oral argument because the

facts and legal contentions are adequately presented in the

materials before the court and argument would not aid the

decisional process. 

DISMISSED
EXHIBIT
32.1


CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





Yisroel
Guttfreund, the President and Chief Executive Officer, Chairman, and Director of
Watchtower, Inc., certifies, under the standards set forth and solely for the
purposes of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that, to his knowledge, the Annual Report on Form
10-K of the Company for the fiscal year ended December 31, 2008, fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934 and information contained in that Form 10-K fairly presents, in all
material respects, the financial condition and  results of operations
of the Company.





(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and





(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Registrant.








Date:
      March 27, 2009
              
              WATCHTOWER,
      INC.By.
              /s/
      Yisroel
      GuttfreundName:
              Yisroel
      GuttfreundTitle:
              President
      and Chief Executive Officer, Chairman, and Director
                (Principal
      Executive, Financial and Accounting
Officer)








A signed
original of this written statement required by Section 906 has been provided to
the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.
Claudia Angelica ALLEN, Appellant/Petitioner(s), v. OCWEN LOAN SERVICES, LLC, Appellee/Respondent(s).

CASE NO.: 2D18-2737

District Court of Appeal of Florida, Second District.

July 24, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Appeal is dismissed as moot.
10-301 United States v. Capeci UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT 

## SUMMARY ORDER
RULINGS BY SUMMARY ORDER DO NOT HAVE PRECEDENTIAL EFFECT. CITATION TO A SUMMARY ORDER FI LED ON OR AFTER JANUARY 1, 2007, IS PERMITTED AND IS GOVERNED BY THIS COURT’S LOCAL RULE 32.1.1 AND FEDERAL RULE OF APPELLATE PROCEDURE 32.1. WHEN CITING A SUMMARY ORDER IN A DOCUMENT FILED WITH THIS COURT, A PARTY MUST CITE EITHER THE FEDERAL APPENDIX OR AN ELECTRONIC DATABASE (WITH THE NOTATION “SUMMARY ORDER”). A PARTY CITING A SUMMARY ORDER MUST SERVE A COPY OF IT ON ANY PARTY NOT REPRESENTED BY COUNSEL.

At a stated Term of the United States Court of Appeals for the Second Circuit, held at the Daniel Patrick Moynihan United States Courthouse, 500 Pearl Street, in the City of New York, on the 7 thday of June, two thousand eleven, Present: AMALYA L. KEARSE, ROSEMARY S. POOLER, GERARD E. LYNCH, Circuit Judges

.

_____________________________________________ UNITED STATES OF AMERICA, Appellee , -v- 10-301 JERRY CAPECI, Interested-Party-Appellant, MILANA MURCIA, Defendant

. Appearing for Appellant: Stephen Gikow, Media Freedom & Information Access Practicum, Yale Law School, New Haven, CT, Nathan Siegel, Levine Sullivan Koch & Schultz, LLP, Washington, D.C. ( on the brief ).2 Appearing for Appellee: Nicholas L. McQuai d, Assistant United States Attorney for the Southern District of New York (Preet Bharara, United States Attorney for the Southern District of New York; Jesse M. Furman, Assistant United States Attorney for the Southern District of New York, on the brief ) Appeal from the United States District Cour t for the Southern District of New York (Karas, J. ). ON CONSIDERATION WHEREOF, IT IS HEREBY ORDERED, ADJUDGED, AND DECREED that the judgment of said District Court be and it hereby is AFFIRMED

. Jerry Capeci seeks review of the January 6, 2010 order of the United States District Court for the Southern District of New York (Karas, J .) ordering that the transcript of certain proceedings that took place before it continue to be sealed. Capeci sought to unseal the transcript, arguing its sealing violated the First Amendment. We assume the parties’ familiarity with the underlying facts, procedural histor y, and specification of issues for review. For the purposes of this appeal, we assume without deciding that there was a presumptive public right of access to the proceeding in question, and that the presumption of openness may be overcome only “by an overriding interest based on findings that closure is essential to preserve higher values and is narrowly tailored to serve that interest.” Press-Enterprise Co. v. Superior Court of California , 478 U.S. 1, 9 (1986). We find no error with the district court’s reasons for sealing, set forth in its sealed order of January 6, 2010. The government is reminded that should the conditions for unsealing set forth in the sealed order come to pass, it is under a continuing obligation to inform the district court. Accordingly, the judgment of the district court hereby is AFFIRMED.

FOR THE COURT: Catherine O’Hagan Wolfe, Clerk